Patents by Inventor LIEYI WU

LIEYI WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • All-trans retinoic acid injectant and application
    Patent number: 10952984
    Abstract: The present disclosure provides an all-trans retinoic acid injectable formulation and its application for a preparation of a pharmaceutical product for treating tumor. The all-trans retinoic acid injectable formulation includes all-trans retinoic acid and solubilizers. The apparent solubility of the all-trans retinoic acid is increased from 0.01 mg/mL to 0.1 mg/mL or more. The injectable formulation can reduce the activity of an infiltrated immuno-suppressive cell population within blood or tumor tissue of a cancer patient, and improve immune clearing effects against tumors. It can be applied independently or together with other pharmaceutical products to inhibit tumor growth and prevent tumor recurrence.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 23, 2021
    Assignee: HIGHFIELD BIOPHARMACEUTICAL CORPORATION
    Inventors: Yuhong Xu, Xiaolong Chen, Anjie Zheng, Lieyi Wu
  • ALL-TRANS RETINOIC ACID INJECTANT AND APPLICATION
    Publication number: 20190282530
    Abstract: The present disclosure provides an all-trans retinoic acid injectable formulation and its application for a preparation of a pharmaceutical product for treating tumor. The all-trans retinoic acid injectable formulation includes all-trans retinoic acid and solubilizers. The apparent solubility of the all-trans retinoic acid is increased from 0.01 mg/mL to 0.1 mg/mL or more. The injectable formulation can reduce the activity of an infiltrated immuno-suppressive cell population within blood or tumor tissue of a cancer patient, and improve immune clearing effects against tumors. It can be applied independently or together with other pharmaceutical products to inhibit tumor growth and prevent tumor recurrence.
    Type: Application
    Filed: August 17, 2017
    Publication date: September 19, 2019
    Applicant: HIGHFIELD BIOPHARMACEUTICAL CORPORATION
    Inventors: YUHONG XU, XIAOLONG CHEN, ANJIE ZHENG, LIEYI WU